Skip to content
Screener

SG&A at other companies

AbbVie logo
AbbVieABBV
$3.63B+11.7%
Bausch + Lomb logo
Bausch + LombBLCO
$588M+1.6%
Opko Health logo
Opko HealthOPK
$52.92M-11.2%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$861M-0.7%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$150.7M+46.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$662.1M+4.4%

Segments

By segment

See full
Branded$25.76M+24.5%
Compounding$6.74M-10.4%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.49B+22.8%
Enterprise value$1.7B+5.6%
P/S5.5×+0.2×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Harrow’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-022254
Line item2026 / For the Three Months Ended March 31,2025 / For the Three Months Ended March 31,
Cost of sales(17,158,000)(15,524,000)
Gross profit27,045,00032,307,000
Operating expenses:
Selling, general and administrative43,230,00040,513,000
Research and development5,895,0003,026,000
Total operating expenses49,125,00043,539,000
Loss from operations(22,080,000)(11,232,000)
Interest expense, net(5,497,000)(6,548,000)

Item 1. Financial Statements (unaudited) Item

FAQ

What is Harrow's SG&A?
Harrow (HROW) reported SG&A of $43.23M in Q1 2026.
How has Harrow's SG&A changed year-over-year?
Harrow's SG&A increased by 6.7% year-over-year, from $40.51M to $43.23M.
What is the long-term trend for Harrow's SG&A?
Over 4 years (2021 to 2025), Harrow's SG&A has grown at a 38.7% compound annual growth rate (CAGR), from $41.32M to $152.91M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Harrow's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude